MHC-I genotype and tumor mutational burden predict response to immunotherapy.

4 c, d), we did find that responders tended to have lower PHBR scores (i.e., better presented mutations) than non-responders, although the trends did not reach statistical significance (Fig. 5 ).

also in 111,027 other papers